News

The significant growth in revenues was due to an increase in sales of existing products in the growing China healthcare market, which included AMDL’s best-selling human placenta extract

Diluted earnings per share, excluding specified items, were $0.73, reflecting 15.9% growth, and $0.03 above the mid-point of Abbott’s previous first-quarter guidance range. Diluted earnings per share under

Biomerica reported operating income from continued operations for the quarter ended February 28, 2009 of $214,101 compared to operating income from continued operations of $118,009 in the year-ago

Daiichi Sankyo Company has filed patent infringement litigations against 11 generics companies for the substance patent and usage patent for levofloxacin hydrate. Daiichi Sankyo brought patent infringement actions

The orphan drug designation provides Oasmia with seven year market exclusivity on the indication when the pharmaceutical is approved. The designation is based on the hypothesis that Paclitaxel

Solzira is the subject of a new drug application (NDA) that is under review by the FDA as a potential treatment for moderate-to-severe primary restless legs syndrome (RLS).

As part of the agreement, Syntonix gains access to Zenobia’s technology and expertise in structural biology, crystallization and X-ray structure determination. Zenobia has completed three unique protein structures

Simponi is a new, human anti-tumor necrosis factor (TNF) monoclonal antibody that was generated by Medarex’s UltiMAb technology that targets and neutralizes both the soluble and membrane-bound forms

The long-term cardiac monitoring for detection of atrial fibrillation (AF) after cryptogenic stroke is a pilot study involving five centers in Canada and the US. The primary endpoint